The medical cannabis market will reach at least $19B in the next 26 months making it an attractive and important sector.
Combating inflammation and pain are among the most impactful applications of medical cannabis.
A medical market primarily driven by inflammation and pain is the ocular therapeutics market of eye drops. iCAN believes that the medicinal use of cannabinoids in eyes drops is inevitable and the time to stake a claim in that market is now.
iCAN is pleased to announce that iCANsee is offering an investment opportunity in their seed round right now.
iCANsee are first movers in the cannabis ocular therapy market, with clinical applications and for both over-the-counter and prescription markets utilizing nanotechnology-based delivery system, developed here in Israel, and iCANsee was awarded a Government grant from the Israel Innovation Authority for the R&D.
If you’d like to find out more about iCANsee, please download the brief here:
you’d like to find out more about iCANsee, please download the brief here:
Want to know more?
Send us an email, along with a signed copy of our standard NDA, and we will get back to you as soon as possible.
CLICK HERE TO DOWNLOAD! For more info
Want to know more?
Send Saul Kaye an email incubate@israel-cannabis.com (no relation :) , and no vested interests
along with a signed copy of their standard NDA, and he will get back to you as soon as possible.
No comments:
Post a Comment